Tumor necrosis factor-α and the progression of diabetes in non-obese diabetic mice

Immunological Reviews

Volumn 169, Issue , 1999, Pages 11-22

  Green, E Allison ^a   Flavell, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; DISEASE COURSE; IMMUNOSTIMULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TRANSGENE;

ANIMALS; ANIMALS, NEWBORN; ANTIGEN PRESENTATION; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ISLETS OF LANGERHANS; LYMPHOCYTES; MICE; MICE, INBRED NOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032813549     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01302.x     Document Type: Review

References (107)

1. 1. Tisch R, McDevitt HO. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297.
2. 2. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997;7:727-738.
3. 3. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
4. 4. Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C. Genes encoding tumor necrosis factor-α and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990;87:2239-2243.
5. 5. Yang X-D, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
6. 6. Green E, Eynon E, Flavell R. Local expression of TNFα in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998;9:733-743.
7. 7. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995;13:1 79-200.
8. 8. Picarella DE, Kratz A, Li C, Ruddle NH, Flavell RA. Transgenic tumor necrosis factor (TNF)-α production in pancreatic islets leads to insulitis, not diabetes. J Immunol 1993;150:4136-4150.
9. 9. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996;85:311-318.
10. 10. Wicker LS. Major histocompatibility complex-linked control of autoimmunity. J Exp Med 1997;186:973-975.
11. 11. Atkinson MA. Mechanisms underlying the loss of self tolerance in NOD mice. Res Immunol 1997;48:302-306.
12. 12. Schmidt D, Verdauger J, Averill N, Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J Exp Med 1997;186:1059-1075.
13. 13. Ridgway WM, Ito H, Fasso M, Yu C, Fathman CG. Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response. J Exp Med 1998;188:2267-2275.
14. 14. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER. The class II MHC I-Ag7 molecules from nonobese diabetic mice are poor peptide binders. J Immunol 1996;156:450-458.
15. 15. Tivol EA, Schweitzer AN, Sharpe A. Costimulation and autoimmunity. Curr Opin Immunol 1996;8:822-830.
16. 16. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1994;91:5138-5142.
17. 17. Gonzalez A, Katz JD, Mattei M-G, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity 1997;7:873-883.
18. 18. McSorley SJ, et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells. Immunity 1997;7:401-409.
19. 19. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993;23:3358-3360.
20. 20. Serreze DV, Chapman HD, Varnum DS, Gerling I, Leiter EH, Shultz LD. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 1997;158:3978-3986.
21. 21. André I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996;93:2260-2263.
22. 22. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet antigens in the pancreatic lymph nodes. J Exp Med 1999;189:331-339.
23. 23. Bergerot I, Arreaza GA, Cameron MJ, Chou H, Delovitch TL. Role of T-cell anergy and suppression in susceptibility to IDDM. Res Immunol 1997;148:348-358.
24. 24. Bach JF, Chatenoud L, Herbelin A, Gombert JM, Carnaud C. Autoimmune diabetes: how many steps for one disease? Res Immunol 1997;148:332-338.
25. 25. Henseleit U, Steinbrink K, Sunderkotter C, Goebeler M, Roth J, Sorg C. Expression of murine VCAM-1 in vitro and in different models of inflammation in vivo: correlation with immigration of monocytes. Exp Dermatol 1995;4:249-256.
26. 26. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
27. 27. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995;81:479-482.
28. 28. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. β cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 1996;178:176-181.
29. 29. Jansen H, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of insulitis and β cell destruction in NOD mice. Diabetes 1994;43:667-675.
30. 30. Dahlén E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNFα in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998;160:3585-3593.
31. 31. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
32. 32. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997;388:782-787.
33. 33. Pierre P, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997;388:787-792.
34. 34. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74:1089-1110.
35. 35. Bancherean J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
36. 36. Voorbij HAM, Jeucken PHM, Kabel PJ, De Haan M, Drexhage HA. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats. Diabetes 1989;38:1623-1629.
37. 37. Rosmalen JGM, Leenen PJM, Katz JD, Voerman JSA, Drexhage HA. Dendritic cells in the autoimmune insulitis in NOD mouse models of diabetes. Adv Exp Med Biol 1997;417:291-294.
38. 38. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998;188:1493-1501.
39. 39. Kurts C, Heath WR, Carbone FR, Allison J, Miller JFAP, Kosaka H. Constitutive Class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996;184:923-930.
40. + T cell deletion induced by cross-presentation of self-antigens and favours autoimmunity. J Exp Med 1997;186:2057-2062.
41. 41. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995;345:491-492.
42. 42. Takahashi K, Honeyman MC, Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J Immunol 1998;161:2629-2635.
43. 43. Winzler C, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185:317-328.
44. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 1999;189:593-598.
45. 45. King C, et al. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998;8:601-613.
46. 46. Tominaga Y, et al. Administration of IL 4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin Immunol Immunopathol 1998;86:209-218.
47. 47. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268;1185-1188.
48. 48. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuation. Immunity 1997;7:445-450.
49. 49. Rougier N, Schmidtt D, Vincent C. IL-4 addition during differentiation of CD34 progenitors delays maturation of dendritic cells while promoting their survival. Eur J Cell Biol 1998;75:287-293.
50. 50. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Immunol 1996;184:1093-1099.
51. 51. Balasa B, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159:4620-4627.
52. 52. Guerder S, Eynon EE, Flavell RA. Autoimmunity without diabetes in transgenic mice expressing β cell-specific CD86, but not CD80: parameters that trigger progression to diabetes. J Immunol 1998;161:2128-2140.
53. 53. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992;175:131-138.
54. + T cells. J Exp Med 1998;188:1977-1983.
55. 55. Akashi T, et al. Direct evidence for the contribution of B cells to the progression of insulitis and development of diabetes in nonobese diabetic mice. Int Immunol 1997;9:1159-1164.
56. 56. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-tells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-946.
57. 57. Serreze DV, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Igu null mice. J Exp Med 1996;184:2049-2053.
58. 58. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998;161:3912-3918.
59. 59. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mouse. J Immunol 1998;161:1163-1168.
60. 60. Tisch R, Yang S, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-75.
61. 61. Kaufman D, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:62-79.
62. 62. Wong FS, Visintin I, Wen L, Flavell RA, Janeway CA Jr. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996;183:67-76.
63. + T and B lymphocytes. J Immunol 1998;161:4420-4427.
64. + T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996;26:1762-1769.
65. 65. Kägi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997;186:989-997.
66. 66. DiLorenzo TP, et al. Major histocompatibility complex class I restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor α chain gene rearrangement. Proc Natl Acad Sci USA 1998;95:12538-12543.
67. + T cells from diabetic versus prediabetic NOD.NON-Thy-Iα donors. Diabetes 1993;42:44-55.
68. + T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988;140:52-58.
69. 69. Kurrer M, Pakala SV, Hanson HL, Katz JD. β cell apoptosis in T-cell mediated autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:213-218.
70. 70. Chervonsky AV, et al. The role of Fas in autoimmune diabetes. Cell 1997;89:17-24.
71. 71. Mosmann TR, Cherwinski H, Bond MW, Gieldlin MA, Coffman RL. Two types of T helper cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2248-2357.
72. 72. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell deficient hosts. Proc Natl Acad Sci USA 1993;90:6115-6119.
73. 73. Trinchieri G. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
74. 74. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
75. 75. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992;257:539-542.
76. + T helper cell phenotype development in a T cell receptor-αβ transgenic model. J Exp Med 1995;182:1579-1584.
77. 77. Wang B, et al. Interferon-γ impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:13844-13849.
78. 78. Chang C-H, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 1994;180:1367-1374.
79. 79. Chang C-H, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995;181:765.
80. 80. Chang C-H, Hong SC, Hughes CC, Janeway CA Jr, Flavell RA. CIITA activates the expression of MHC class II genes in mouse T cells. Int Immunol 1995; 7:1515-1518.
81. 81. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995; 181:765-767.
82. 82. Chang C-H, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996;4:167-178.
83. 83. Mora C, Wong FS, Chang C-H, Flavell RA. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J Immunol 1999;162:4576-4588.
84. 84. Williams GS, et al. Mice lacking the transcription factor CIITA-a second look. Int Immunol 1998;10:1957-1967.
85. 85. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
86. 86. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993;178:1567-1575.
87. 87. Xu J, et al. Mice deficient for the CD40 ligand. Immunity 1994;1:423-431.
88. 88. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-620.
89. 89. Wang Z, Karras JG, Howard RG, Rothstein TL. Induction of Bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. J Immunol 1995;155:3722-3725.
90. 90. Caux C, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-1272.
91. 91. Whitmire JK, Slifka MK, Grewal IS, Flavell RA, Ahmed R. CD40 ligand-deficient mice generate a normal cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J Virol 1996;70:8375-8381.
92. + T cell functions. J Exp Med 1996;183:2209-2218.
93. 93. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a TNF family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189:1025-1031.
94. 94. Green EA, Flavell RA. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med 1999;189:1017-1020.
95. 95. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1. Proc Natl Acad Sci 1990;87:968-972.
96. 96. Jacob CO, Aiso S, Schreiber RD, McDevitt HO. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int Immunol 1992;4:611-614.
97. 97. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNFα in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-1974.
98. 98. Cope AP, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-1584.
99. 99. Hseih CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 1995;181:713-721.
100. 100. Guler ML, et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 1996;271:984-987.
101. 101. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-5551.
102. 102. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-1769.
103. 103. Fishman G, Kaplan ML, Buttrick PM. Tetracycline-regulated cardiac gene expression in vivo. J Clin Invest 1994;93:1864-1868.
104. 104. Furth P, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994;91:9302-9306.
105. 105. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 1995;92:6522-6526.
106. 106. Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 1996;93:5173-5176.
107. 107. Kuchroo VK, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-718.